AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01372839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
Study NCT01372839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Usual care, but statin dose should not be higher than that described in exclusion criteria
Study NCT02595580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucopred
Study NCT01200290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: 120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
Study NCT01681615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylate
Description: 1-2 drops
Study NCT01681615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: 1 drop
Study NCT03350399 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: placenta growth factor
Description: estimation level of derum placenta growth factor
Study NCT01217437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01217437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT01217437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT00691249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Raw
Description: Low Dose- 70g bar
Study NCT00691249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Raw
Description: High Dose- 100g bar
Study NCT00691249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Cooked
Description: Low Dose- 70g bar
Study NCT00691249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4-Cooked
Description: High dose: 100g bar
Study NCT00691249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Shredded Wheat
Description: 70g bar
Study NCT05572593 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (PGx) genetic testing
Description: A buccal swab to collect cells from the inside the cheek
Study NCT05572593 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomics (PGx) genetic testing
Description: A buccal swab to collect cells from the inside the cheek
Study NCT02712489 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00958542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical fusion
Description: Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
Study NCT02413281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablets, single administration
Study NCT02413281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Sublingual tablets, single administration
Study NCT02413281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablets, single administration
Study NCT01511341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
Study NCT04785105 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04116801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microsurgical resection
Description: resection of cerebral metastases by microsurgery
Study NCT04116801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microsurgical resection
Description: resection of cerebral metastases by microsurgery
Study NCT02222870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
Study NCT02222870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Description: 0.5 mL, Intramuscular (2014-2015 formulation)
Study NCT03008798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal Medicine C-117
Description: C117 formula including 2 herbals and 2 insects
Study NCT03008798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo of Herbal Medicine C-117
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denintuzumab mafodotin
Description: Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m\^2 by IV infusion, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ifosfamide
Description: 5000 mg/m\^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
Study NCT02592876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m\^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
Study NCT01435772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMN 701
Description: GILT-tagged recombinant human GAA
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0.0mg, once daily, 14 day
Study NCT03511196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adaptive Androgen Deprivation Therapy (ADT)
Description: ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
Study NCT03511196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Prednisone 5 mg once a day with food.
Study NCT03511196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Abiraterone 1000 mg daily with empty stomach.
Study NCT02425345 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 15mg, twice daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 60mg, twice daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, oral, 150mg, twice daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 300mg, twice daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 450mg, twice daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, To be determined (TBD), once daily, 14 day
Study NCT01290575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820132
Description: Capsule, Oral, 5 mg, twice daily, 14 day
Study NCT02334826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI -BVS
Description: All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
Study NCT02334826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
Study NCT00736294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
Study NCT00736294 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
Study NCT03253536 — intervention group
Intervention type: OTHER
Intervention: observational
Description: none (observational study)
Study NCT00913211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: 600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
Study NCT00913211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor learning training
Description: one hour of repeated finger tracking movements toward a changing target.
Study NCT00913211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS and Tracking
Description: Combination of rTMS and finger tracking
Study NCT00913211 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Sham treatment of rTMS
Study NCT00604747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Structure practice
Description: there were 2 groups which received random practice and constant practice during acquisition phase
Study NCT04633772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Intravenous supplementation of Angiotensin-(1-7)
Study NCT04633772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9%
Study NCT03163537 — intervention group
Intervention type: DEVICE
Intervention: HealthPatch
Description: Smart patch that is able to measure stress real time using an algorithm between HR and HRV
Study NCT00994227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrectomy for macular disease
Description: three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
Study NCT01744158 — intervention group
Intervention type: OTHER
Intervention: No intervention applicable
Description: Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~* differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~* measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~* measurement of severity of spasticity using the modified Ashworth score~* description of presence of chorea or athetosis~* classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~* classification of fine motor abilities using the manual ability classification system (MACS)~* collection of demographic data and associated medical history
Study NCT01616160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: 2 sprays/nostril BID
Study NCT01925976 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individualized dietetic intervention-eating habits
Description: The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
Study NCT03328598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive psychology therapy group
Description: This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
Study NCT03328598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience promotion therapy group
Description: The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
Study NCT03328598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Controlled routine activity
Description: Conventional community activities is viewed as an active comparator for controlled group.
Study NCT02362737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active and Healthy Brotherhood (AHB)
Description: Participants will attend group sessions led by trained group facilitators. The group sessions will be \~16 weekly meetings of \~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
Study NCT04497012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg/kg/day Iron Sulfate
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Study NCT04497012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 mg/kg/day Iron Sulfate
Description: Iron Sulfate will be given in liquid form via nasal or oral gastric tube with feeds.
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT00717652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbutin, tretinoin, triamcinolone
Description: arbutin, tretinoin, triamcinolone
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02912559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT02912559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00717652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triluma
Description: Hydroquinone, Fluoncinolone, Tretinoin
Study NCT02745483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Separable clustered electrodes
Description: patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
Study NCT01100632 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng, vitamins, minerals
Description: 2 capsules per day
Study NCT01100632 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Gelatin capsule
Description: 2 capsules per day
Study NCT04030234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP treatment group
Description: Participants in the Intensive BP treatment group have a goal of SBP \<120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics
Study NCT04030234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP treatment group
Description: Participants in the Standard BP treatment group have a goal of SBP \<140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
Study NCT00401518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-randomized ACADIA® Facet Replacement System
Description: Non-randomized investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
Study NCT02912559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01274338 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01274338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02248077 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AutoloGel
Study NCT02248077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care (UCC)
Study NCT04401566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal myofascial release
Description: Internal myofascial trigger point release therapy consist of 30 minutes massage directly to the pelvic floor musculature by vaginally. Patients were instructed in internal myofascial relase techniques. Experienced pelvic health physiotherapist (A.B.) to use her fingers with a lubricated glove when the finger could easily reach internal trigger points and follows these steps: (a) finding internal and external trigger points associated with pelvic muscles, especially around sensitive areas of the vagina, anus, and/or pelvic floor; (b) releasing with the fingers the trigger point associated pelvic muscle tension by carefully pressing on the trigger point
Study NCT04401566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External myofascial release
Description: Eksternal myofascial trigger point release therapy consist 30 minutes massage to the abdominal wall, gluteal area and adductors and hamstring muscles. Pain in trigger points may exist at both locations of muscle insertion as well as in the belly and lower extremity of the muscle.